


171, 172, 174, 175 or 176.



What is claimed is:

A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding Phospholipid scramblase I, wherein said compound specifically hybridizes with and inhibits the expression of Phospholipid scramblase I.

- 2. The compound of claim 1 which is an antisense oligonucleotide.
- 3. The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 22, 23, 25, 27, 28, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 69, 70, 75, 77, 78, 81, 82, 86, 87, 89, 96, 97, 99, 101, 102, 103, 104, 105, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 169, 170,
- 4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
- 5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothicate linkage.
- 6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 9. The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
- 10. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.



- 12. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
- 13. The composition of claim 12 further comprising a colloidal dispersion system.
 - 14. The composition of claim 12 wherein the compound is an antisense oligonucleotide.
- 15. A method of inhibiting the expression of Phospholipid scramblase I in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of Phospholipid scramblase I is inhibited.
- 16. A method of treating an animal having a disease or condition associated with Phospholipid scramblase I comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of Phospholipid scramblase I is inhibited.
- 17. The method of claim 16 wherein the disease or condition is a hyperproliferative condition.
- 18. The method of claim 17 wherein the hyperproliferative condition is cancer.
- 19. The method of claim 16 wherein the disease or condition is inflammation.
- 20. The method of claim 16 wherein the disease or condition is an immune disorder.